WO2001051070A1 - Substance eem-s physiologiquement active issue de champignons, methode de production de ladite substance et medicaments - Google Patents
Substance eem-s physiologiquement active issue de champignons, methode de production de ladite substance et medicaments Download PDFInfo
- Publication number
- WO2001051070A1 WO2001051070A1 PCT/JP2001/000072 JP0100072W WO0151070A1 WO 2001051070 A1 WO2001051070 A1 WO 2001051070A1 JP 0100072 W JP0100072 W JP 0100072W WO 0151070 A1 WO0151070 A1 WO 0151070A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mushroom
- active substance
- physiologically active
- eem
- molecular weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- the present invention relates to an anti-mushroom obtained from at least one edible mushroom selected from shiitake, enokitake, bunashimeji, oyster mushroom, maitake, fukuguchi bamboo, nameko, hatakeshimeji, eryngii, matsutake, ganoderma mushrooms, and moss mushrooms such as mushrooms.
- the present invention relates to a substance having a physiological activity such as a cancer activity, an antiallergic activity, an immunostimulatory activity, an antioxidant activity, a method for producing the same, and a preparation containing the physiologically active substance.
- the present inventors have been conducting detailed research on the physiological activity of mushrooms over time, and as a result, have found that certain mushrooms have anticancer, immunostimulatory, antioxidant, blood pressure and blood glucose lowering effects. It has been known to exhibit physiological activities such as action. However, depending on the type of mushrooms, if they work well, despite their lack of activity or being very weak, their effects are overly advertised and released.
- the present inventors have found that the anticancer activity of mushrooms in particular is due to the polysaccharides contained therein from reliable research results based on vast research data, and studied glucan, which is a polysaccharide of mushrooms.
- glucan which is a polysaccharide of mushrooms.
- the pure simple polysaccharide, glucan was found to be active when injected but not orally.
- An object of the present invention is to provide a method for selecting a mushroom containing a substance having a physiological activity such as an anticancer effect and an immunostimulating effect at a high concentration by oral administration, and efficiently collecting the physiologically active substance. It is intended to provide a preparation prepared by making the obtained active substance suitable for use. Disclosure of the invention
- the present inventors have conducted various studies to solve the above-mentioned problems.
- the fruiting bodies and / or mycelia of edible mushrooms contain a large amount of an orally active substance
- the extract of mushrooms in water or an aqueous solvent or a mixture thereof contains an orally active substance, and these extracts are further processed by the molecular sieve method to obtain a low molecular weight part and a high molecular weight part.
- the present inventors have found that those having a constant molecular weight range excluding the molecular portion exhibit excellent physiological activity, and thus completed the present invention.
- the present invention provides at least one mushroom selected from shiitake, enokitake, bunashimeji, oyster mushroom, nameko, maitake, fukuguchi mushroom, hatakeshimeji, eryngii, matsutake, reishi and mesimakobu in water, a hydrophilic solvent or a mixture thereof. It is extracted with a solvent, and then the extract is treated by the molecular sieve method to provide a physiologically active substance EEM-S obtained by collecting a portion having a molecular weight of 6,000 to 60,000. is there.
- the present invention also provides a method for producing the bioactive substance EEM-S. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a diagram of an ultraviolet-visible absorption curve of the physiologically active substance EEM-SB obtained in Example 1.
- the solvent is water.
- FIG. 2 is a diagram of an ultraviolet-visible absorption curve of the physiologically active substance EEM-SS obtained in Example 2.
- the solvent is water.
- FIG. 3 is a diagram of an ultraviolet-visible absorption curve of the physiologically active substance EEM-SM obtained in Example 3.
- the solvent is water.
- FIG. 4 is a diagram of an ultraviolet-visible absorption curve of the physiologically active substance EEM-SN obtained in Example 4.
- the solvent is water.
- FIG. 5 is a diagram of an ultraviolet-visible absorption curve of the physiologically active substance E EM-SE obtained in Example 5.
- the solvent is water.
- FIG. 6 is a diagram of an infrared absorption curve of the physiologically active substance EEM-SB obtained in Example 1 measured by the ATR method.
- Fig. 7 shows the red color of the bioactive substance E EM-SE obtained in Example 5 measured by the ATR method. It is a figure of an outside line absorption curve.
- FIG. 8 is a chart of 'H-NMR (D 20 ) of the bioactive substance E EM-SB obtained in Example 1.
- FIG. 9 is a chart of 'H-NMR (D 20 ) of the bioactive substance E EM-SE obtained in Example 5.
- FIG. 10 is a chart of ' 3 C-NM R (D 20 ) of the physiologically active substance E EM-SB obtained in Example 1.
- FIG. 11 is a chart of ' 3 C-NM R (D 2 ⁇ ) of the physiologically active substance E EM-SE obtained in Example 5.
- the physiologically active substance E EM_S of the present invention is an edible mushroom such as shiitake, enokitake, bunashimeji, oyster mushroom, nameko, maitake, fukuguchi bamboo, hatakeshimeji, eryngii, matsutake, reishi and mesimakob. It can be obtained by extracting at least one finely pulverized substance (hereinafter referred to as "mushroom") of the substance and the mycelium with water and / or a hydrophilic solvent.
- a hydrophilic solvent used for this extraction a lower alcohol having 1 to 4 carbon atoms is preferably used.
- the extraction of the fraction containing the physiologically active substance EEM-S from the above mushrooms is performed, for example, by adding an appropriate amount of a hydrophilic solvent such as water or lower alcohol to the raw material mushrooms, for example, at about 80 to 98 ° C.
- a hydrophilic solvent such as water or lower alcohol
- the extraction is carried out at a temperature of 90 to 98 ° C. under reflux for about 1 to 4 hours, preferably for 2 to 4 hours.
- a solvent is used in an amount of about 3 to 10 parts by weight based on the weight of the mushroom.
- the extract obtained as described above can be used to separate solid impurities by filtration or the like, if necessary, and then the solvent can be distilled off under reduced pressure to collect the extract as a solid.
- the solid thus obtained shows its activity by oral administration by itself, and can be used as it is.However, in order to enhance the activity, the extract is treated with a molecular sieve to remove unnecessary parts, and the pressure is reduced again.
- the molecular weight of 6,000 to 60,000 obtained by The part can be used as a bioactive substance EEM_S.
- the molecular sieve used for the above purpose includes a molecular sieve (flat membrane), a hollow filtration membrane, a dialysis membrane, a molecular sieve chromatograph, and the like.
- EEM_S For the separation and acquisition of EEM_S, a method using these can be applied as appropriate.
- a method for separating and obtaining the physiologically active substance EEM-S will be described as follows, taking the case of using module type hollow filtration as an example. That is, the water and / or hydrophilic solvent extract of the mushroom (fraction containing the physiologically active substance EEM-S) obtained by extracting the mushrooms as described above is first applied to a low-molecular-weight fractionation membrane module, for example, AIP-301 3, A
- IP-2013 or AIP-010 (Asahi Kasei Kogyo) to remove low-molecular substances (substances with a molecular weight of 6,000 or less).
- the concentrated solution from which the low-molecular substances have been removed is treated with a high-molecular-weight fractionation module, for example, AHP-3013, AHP-2013, or AHP-1010 (manufactured by Asahi Kasei Corporation).
- a physiologically active substance EEM-S having a molecular weight of 6,000 to 60,000 can be obtained.
- the molecular weight in the present invention means the molecular weight obtained by the molecular sieve method. More precisely, the molecular weight on the low molecular weight side is AIP-3013 or a low molecular weight fraction membrane module equivalent thereto. It is a value measured using a rule. Similarly, the molecular weight on the polymer side is a value measured using an AHP-3013 or equivalent low molecular weight separation module.
- EEM-S The bioactive substances of mushrooms obtained in this way are collectively described as EEM-S.
- mushroom mycelium when used as a raw material, bioactive substances from mushrooms are collected depending on the culture conditions. The ratios are different, and it is necessary to select the optimal medium, culture temperature, etc. Also, depending on the type of mushroom, it may show slightly different physicochemical properties.
- E EM-S a physiologically active substance E EM-S (hereinafter sometimes referred to as “E EM-SB”) produced from Bunashimeji as a raw material has the physicochemical properties shown in Example 1 described later.
- E EM-S the physiologically active substance E EM-S (hereinafter sometimes referred to as “EE M_SE”) manufactured from enokitake mushrooms has the physicochemical properties shown in Example 5 below. It is.
- the bioactive substances EEM-S obtained from Shiitake, Maitake and Nameko hereinafter sometimes referred to as “EEM-SS”, “EEM-SM” and “EEM-SN” respectively) are also shown in the figures. 1 to 5 show the ultraviolet-visible absorption.
- the physiologically active substance E EM-S described above can exert its physiological activity by oral administration, but the oral intake for achieving the intended effect depends on the age, weight, purpose, etc. of humans. In general, it is preferable that the EEM_S per adult per day is in the range of 200 to 5000 mg, preferably in the range of 1,000 to 3000 mg, and it is appropriate to take this amount several times a day. would.
- the physiologically active substance EEM-S of the present invention can be used as a powder, granule, capsule, or liquid by a conventional method. However, if left as it is in the air, it may absorb moisture, discoloration and deterioration. It is preferable to use it as a tablet coated with mum coat.
- As the film coat material used for this purpose soy peptide, shell resin material, and the like are preferable, and other film coat materials may not be able to sufficiently prevent moisture absorption, and may cause discoloration and deterioration. It can happen.
- Example 1 an anticancer effect was shown as a physiological activity.
- the substance of the present invention is not limited to the anticancer property and has the above-mentioned physiological activity.
- the concentrated solution is filtered using a module type hollow filtration membrane for polymer fractionation, AHP-30-13 (manufactured by Asahi Chemical Industry Co., Ltd.) to remove high-molecular substances (molecular weight: 50,000 or more), and the external solution is again low-molecular-weight.
- AHP-30-13 manufactured by Asahi Chemical Industry Co., Ltd.
- UV absorption measured UV absorption of 370 to 190 nm in aqueous solution
- Fig. 8 shows the chart.
- the chart is shown as FIG.
- Aspartic acid 9.0%, glutamic acid; 16.1%, glycine; 9.1%, alanine; 12.5%, norine; 5.7%, arginine; 5.6%, and aged lunitin; 7.8%.
- FIG. 2 shows an ultraviolet absorption curve of the thus obtained physiologically active substance EEM-SS in an aqueous solution.
- the EEM-SS thus obtained can be converted into a solid powder by freeze-drying, and further tableted to obtain a tablet.
- PM-2 molecular fluid membrane
- a dialysis membrane to remove low molecular weight fractions (molecular weight 6,000 or less).
- the high molecular fraction is removed from the inner solution using a hollow molecular membrane (AHP-3013), and the active substance EEM-SM is obtained.
- FIG. 3 shows an ultraviolet absorption curve of the obtained physiologically active substance E EM-SM in an aqueous solution.
- Nameco 1000 g is extracted with hot water, filtered by suction through a molecular fluid membrane (PM-2, manufactured by Otsuka Jitsugyo Co., Ltd.) to remove the cells, dialyzed by running water through a dialysis membrane, and subjected to low molecular weight fractionation (molecular weight 6). , 000 or less).
- the high molecular fraction is removed from the internal solution using a hollow molecular fluid membrane (AHP-3013) to obtain an active substance EEM-SN.
- AHP-3013 hollow molecular fluid membrane
- the polymer-containing fraction is treated with a molecular fluid membrane PM-10 to remove the polymer substance (50,000 or more), and freeze-dried to obtain a substance with a high molecular weight of 6,000 to 50,000 and high EEM-SE content.
- UV absorption measured UV absorption of 370 to 190 nm in aqueous solution
- Fig. 11 shows the chart.
- Aspartic acid 9.1%, Glutamic acid; 17.7%, Glycine; 14.8 %, Alanine; 21.9%, barin; 11.8%, arginine: 6.8%, ornithine: 12.6%.
- Powders were prepared using the physiologically active substance EEM-S obtained in Examples 1, 2, 3, or 5, and the following anticancer tests were performed. The survival rate in the anti-cancer test was compared with the control group to determine the anti-cancer activity. Table 1 shows the results.
- a substance having high physiological activity can be efficiently obtained easily from edible mushrooms, and a product useful as a medicine or health food can be obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Preparation Of Fruits And Vegetables (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001551493A JP4728551B2 (ja) | 2000-01-12 | 2001-01-11 | 茸からの生理活性物質eem−s、その製造方法および医薬 |
AT01900649T ATE311896T1 (de) | 2000-01-12 | 2001-01-11 | Physiologisch aktive substanz eem-s aus pilzen, herstellungsprozess und medikamente davon |
EP01900649A EP1247529B1 (en) | 2000-01-12 | 2001-01-11 | Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs |
DE60115596T DE60115596T2 (de) | 2000-01-12 | 2001-01-11 | Physiologisch wirksamer stoff eem-s aus pilzen, verfahren zu seiner herstellung, und davon abgeleitete arzneimittel |
AU2001225479A AU2001225479A1 (en) | 2000-01-12 | 2001-01-11 | Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs |
US10/169,099 US6783771B2 (en) | 2000-01-12 | 2001-01-11 | Physiologically active substance EEM-S originating in mushrooms, process for producing the same and drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000/37220 | 2000-01-12 | ||
JP2000037220 | 2000-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001051070A1 true WO2001051070A1 (fr) | 2001-07-19 |
Family
ID=18561141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/000072 WO2001051070A1 (fr) | 2000-01-12 | 2001-01-11 | Substance eem-s physiologiquement active issue de champignons, methode de production de ladite substance et medicaments |
Country Status (9)
Country | Link |
---|---|
US (1) | US6783771B2 (ja) |
EP (1) | EP1247529B1 (ja) |
JP (1) | JP4728551B2 (ja) |
KR (1) | KR100858569B1 (ja) |
CN (1) | CN100346796C (ja) |
AT (1) | ATE311896T1 (ja) |
AU (1) | AU2001225479A1 (ja) |
DE (1) | DE60115596T2 (ja) |
WO (1) | WO2001051070A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011407A1 (ja) * | 2003-07-31 | 2005-02-10 | Takara Bio Inc. | 抗腫瘍性組成物 |
JP2005075740A (ja) * | 2003-08-28 | 2005-03-24 | Hajime Otani | 免疫賦活化組成物、並びにそれが含まれた医薬品、動物薬、食品、飼料及び化粧品 |
WO2006126488A1 (ja) * | 2005-05-25 | 2006-11-30 | Unitika Ltd. | ハナビラタケ抽出物 |
KR100663712B1 (ko) | 2005-05-24 | 2007-01-03 | (주)새롬바이오 | 상황버섯의 균사체로부터 얻은 항당뇨 활성이 있는세포외다당체 및 그 제조방법 |
JP2007031665A (ja) * | 2005-07-29 | 2007-02-08 | Yukiguni Maitake Co Ltd | マイタケから抽出した糖―タンパク複合体 |
JP2008007481A (ja) * | 2006-06-30 | 2008-01-17 | Unitika Ltd | 血管新生阻害剤 |
JP2012077004A (ja) * | 2010-09-30 | 2012-04-19 | Tokyo Institute Of Technology | インスリン分泌促進剤、これを主成分又は添加した糖尿病予防・改善剤及び同食品 |
US8758768B2 (en) | 2001-09-03 | 2014-06-24 | Glycanova As | Process for production of fungal extracellular immune stimulating compounds |
US9072776B2 (en) | 2005-06-15 | 2015-07-07 | Glycanova As | Anti-cancer combination treatment and kit-of-parts |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2396239A1 (en) * | 2000-01-05 | 2001-07-12 | Kureha Chemical Industry Co., Ltd. | Novel immune enhancing compositions |
IL146737A (en) * | 2001-11-26 | 2010-02-17 | Lycored Natural Prod Ind Ltd | Method for protecting lycopene dispersed in tomato fibers |
KR20040033104A (ko) * | 2002-10-11 | 2004-04-21 | 내츄럴네오팜(주) | 천연식물소재 추출물을 이용한 항암효과가 있는 조성물 |
KR20040057973A (ko) * | 2002-12-26 | 2004-07-02 | 요시노부 기타지마 | 플레우로투스 네브로덴시스의 재배방법 및 플레우로투스네브로덴시스를 포함하는 질환 예방 개선제 |
KR20050001730A (ko) * | 2003-06-26 | 2005-01-07 | 진주버섯영농조합 | 암예방 및 치료용 조성물 |
JP4618770B2 (ja) * | 2004-02-12 | 2011-01-26 | 株式会社クレハ | 新規な血圧降下剤および食品 |
KR100590999B1 (ko) * | 2004-10-22 | 2006-06-19 | 주식회사 케이티앤지 | 홍삼 산성다당체 및 표고버섯 함유 항종양 약학조성물 |
US20070026511A1 (en) * | 2005-07-13 | 2007-02-01 | Morrissey Edward S | Methods for the administration of fv and related compositions |
KR100673051B1 (ko) * | 2005-07-29 | 2007-01-22 | 양병근 | 면역 증강 활성을 갖는 맛 버섯 균사체 액체배양물로부터분리한 세포내 생체고분자 |
KR100729213B1 (ko) * | 2005-07-29 | 2007-06-19 | 주식회사 라이벌코리아 | 면역 증강 활성을 갖는 잎새 버섯의 액체배양물로부터분리한 세포외 생체고분자 |
US7597910B2 (en) * | 2005-08-20 | 2009-10-06 | Slgm Medical Research Institute | Compositions and methods for treating prostate disorders |
CN100412186C (zh) * | 2006-03-31 | 2008-08-20 | 浙江大学 | 木蹄层孔菌及液体深层发酵制备木蹄层孔菌菌体的方法 |
JP2008106018A (ja) | 2006-10-27 | 2008-05-08 | Yukiguni Maitake Co Ltd | マイタケ由来の抗インフルエンザウイルス活性を有する物質及びその製造方法 |
JP2011506307A (ja) * | 2007-12-07 | 2011-03-03 | ハンコック ファーム.カンパニー インコーポレーティッド | 桑黄キノコ菌糸体抽出物を有効成分として含む移植片拒絶抑制用組成物 |
US8071105B2 (en) * | 2008-04-21 | 2011-12-06 | Academia Sinica | Reishi F3 sub fraction polysaccharides and methods of using same |
CN103272216B (zh) * | 2013-05-30 | 2015-11-25 | 北京市农林科学院 | 榆黄菇蛋白质提取物及其抗肿瘤的应用 |
US10092609B2 (en) | 2015-01-16 | 2018-10-09 | James A. Wieser | Process for preparing medicinal mycological preparations |
CN106591116A (zh) * | 2016-11-22 | 2017-04-26 | 大连大学 | 一种消除酶解产物抑制酶活性的反应装置 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56127317A (en) * | 1980-03-11 | 1981-10-06 | Banyu Pharmaceut Co Ltd | Preparation of carcinostatic substance |
JPS6219530A (ja) * | 1985-07-19 | 1987-01-28 | Toyo Soda Mfg Co Ltd | 糖蛋白複合体およびその製造法 |
JPS6372629A (ja) * | 1986-09-17 | 1988-04-02 | Kyoritsu Yakuhin Kogyo Kk | 霊芝から生理活性エキスを製造する方法 |
JPH08291078A (ja) * | 1995-04-21 | 1996-11-05 | M I O:Kk | 高血圧及び高脂血症の予防・治療に有効で且つ抗腫瘍作用を有する飲食用キノコタンパク質、及び肥満の予防・治療に有効で且つ抗腫瘍作用を有する飲食用キノコタンパク質、並びにそれらの抽出方法 |
JPH09315994A (ja) * | 1996-05-29 | 1997-12-09 | Sumitomo Forestry Co Ltd | 抗腫瘍活性物質 |
WO1999053937A1 (fr) * | 1998-04-20 | 1999-10-28 | Eishogen Co., Ltd. | Agents immunostimulants et antitumoraux |
JP2000159808A (ja) * | 1998-11-27 | 2000-06-13 | Kobayashi Pharmaceut Co Ltd | 担子菌類菌糸体抽出物の分離、精製方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5657716A (en) * | 1979-10-16 | 1981-05-20 | Morinaga & Co Ltd | Pharmaceutical composition derived from fomes japonicus |
JPS57206618A (en) * | 1981-06-12 | 1982-12-18 | Noda Shiyokukin Kogyo Kk | Preparation of antitumor substance |
JPS58118519A (ja) * | 1981-12-29 | 1983-07-14 | Noda Shiyokukin Kogyo Kk | 抗がん剤 |
JPS6023391A (ja) * | 1983-07-15 | 1985-02-05 | Yamajirushi Jozo Kk | エノキダケ抽出物 |
JPS6023392A (ja) * | 1983-07-15 | 1985-02-05 | Yamajirushi Jozo Kk | エノキダケ抽出物 |
EP0288959B1 (en) * | 1987-04-28 | 1994-01-12 | Meiji Milk Products Company Limited | Novel glycoprotein, production process thereof and immunosuppressive agent containing same as effective ingredient |
CN1032428C (zh) * | 1992-08-15 | 1996-07-31 | 樊菊芬 | 香菇多糖或香菇菌多糖提取新工艺 |
JP2767521B2 (ja) * | 1992-09-04 | 1998-06-18 | 農林水産省食品総合研究所長 | 新規抗腫瘍性蛋白質とその製造法および該蛋白質を有効成分として含有する抗腫瘍剤 |
US5714464A (en) * | 1995-08-09 | 1998-02-03 | Wisconsin Alumni Research Foundation | Anti-viral mushroom extracts |
CN1069650C (zh) * | 1995-12-29 | 2001-08-15 | 中国科学院上海药物研究所 | 香菇多糖的分离纯化方法 |
US5711948A (en) * | 1996-05-29 | 1998-01-27 | Pospelova; Olga L. | Plant-derived, biologically active polysaccharides and method of preparing same |
US6440420B1 (en) * | 2001-03-19 | 2002-08-27 | Xin Liu | Method for extracting oleaginous substances from germination-activated Ganoderma lucidum spores |
-
2001
- 2001-01-11 EP EP01900649A patent/EP1247529B1/en not_active Expired - Lifetime
- 2001-01-11 US US10/169,099 patent/US6783771B2/en not_active Expired - Fee Related
- 2001-01-11 CN CNB018064353A patent/CN100346796C/zh not_active Expired - Fee Related
- 2001-01-11 DE DE60115596T patent/DE60115596T2/de not_active Expired - Fee Related
- 2001-01-11 AU AU2001225479A patent/AU2001225479A1/en not_active Abandoned
- 2001-01-11 JP JP2001551493A patent/JP4728551B2/ja not_active Expired - Fee Related
- 2001-01-11 AT AT01900649T patent/ATE311896T1/de not_active IP Right Cessation
- 2001-01-11 KR KR1020027008805A patent/KR100858569B1/ko not_active IP Right Cessation
- 2001-01-11 WO PCT/JP2001/000072 patent/WO2001051070A1/ja active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56127317A (en) * | 1980-03-11 | 1981-10-06 | Banyu Pharmaceut Co Ltd | Preparation of carcinostatic substance |
JPS6219530A (ja) * | 1985-07-19 | 1987-01-28 | Toyo Soda Mfg Co Ltd | 糖蛋白複合体およびその製造法 |
JPS6372629A (ja) * | 1986-09-17 | 1988-04-02 | Kyoritsu Yakuhin Kogyo Kk | 霊芝から生理活性エキスを製造する方法 |
JPH08291078A (ja) * | 1995-04-21 | 1996-11-05 | M I O:Kk | 高血圧及び高脂血症の予防・治療に有効で且つ抗腫瘍作用を有する飲食用キノコタンパク質、及び肥満の予防・治療に有効で且つ抗腫瘍作用を有する飲食用キノコタンパク質、並びにそれらの抽出方法 |
JPH09315994A (ja) * | 1996-05-29 | 1997-12-09 | Sumitomo Forestry Co Ltd | 抗腫瘍活性物質 |
WO1999053937A1 (fr) * | 1998-04-20 | 1999-10-28 | Eishogen Co., Ltd. | Agents immunostimulants et antitumoraux |
JP2000159808A (ja) * | 1998-11-27 | 2000-06-13 | Kobayashi Pharmaceut Co Ltd | 担子菌類菌糸体抽出物の分離、精製方法 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8758768B2 (en) | 2001-09-03 | 2014-06-24 | Glycanova As | Process for production of fungal extracellular immune stimulating compounds |
US9249438B2 (en) | 2001-09-03 | 2016-02-02 | Glycanova As | Production of fungal extracellular immune stimulating compounds |
US10471135B2 (en) | 2001-09-03 | 2019-11-12 | Glycanova As | Production of fungal extracellular immune stimulating compounds |
WO2005011407A1 (ja) * | 2003-07-31 | 2005-02-10 | Takara Bio Inc. | 抗腫瘍性組成物 |
JP2005075740A (ja) * | 2003-08-28 | 2005-03-24 | Hajime Otani | 免疫賦活化組成物、並びにそれが含まれた医薬品、動物薬、食品、飼料及び化粧品 |
KR100663712B1 (ko) | 2005-05-24 | 2007-01-03 | (주)새롬바이오 | 상황버섯의 균사체로부터 얻은 항당뇨 활성이 있는세포외다당체 및 그 제조방법 |
WO2006126488A1 (ja) * | 2005-05-25 | 2006-11-30 | Unitika Ltd. | ハナビラタケ抽出物 |
JPWO2006126488A1 (ja) * | 2005-05-25 | 2008-12-25 | ユニチカ株式会社 | ハナビラタケ抽出物 |
US9072776B2 (en) | 2005-06-15 | 2015-07-07 | Glycanova As | Anti-cancer combination treatment and kit-of-parts |
JP2007031665A (ja) * | 2005-07-29 | 2007-02-08 | Yukiguni Maitake Co Ltd | マイタケから抽出した糖―タンパク複合体 |
JP2008007481A (ja) * | 2006-06-30 | 2008-01-17 | Unitika Ltd | 血管新生阻害剤 |
JP2012077004A (ja) * | 2010-09-30 | 2012-04-19 | Tokyo Institute Of Technology | インスリン分泌促進剤、これを主成分又は添加した糖尿病予防・改善剤及び同食品 |
Also Published As
Publication number | Publication date |
---|---|
AU2001225479A1 (en) | 2001-07-24 |
CN1416349A (zh) | 2003-05-07 |
DE60115596D1 (de) | 2006-01-12 |
EP1247529A1 (en) | 2002-10-09 |
EP1247529A4 (en) | 2003-05-28 |
ATE311896T1 (de) | 2005-12-15 |
KR100858569B1 (ko) | 2008-09-17 |
CN100346796C (zh) | 2007-11-07 |
KR20020063618A (ko) | 2002-08-03 |
EP1247529B1 (en) | 2005-12-07 |
US20030012798A1 (en) | 2003-01-16 |
JP4728551B2 (ja) | 2011-07-20 |
DE60115596T2 (de) | 2006-06-14 |
US6783771B2 (en) | 2004-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4728551B2 (ja) | 茸からの生理活性物質eem−s、その製造方法および医薬 | |
CN101559084B (zh) | 一种抗肿瘤的药物组合物及其生产方法 | |
CN1213378A (zh) | 从Grifola提取的抗肿瘤物质 | |
CN109276576A (zh) | 白肉灵芝多糖在制备抗肿瘤药物中的用途 | |
KR100385739B1 (ko) | 버섯류의 가공방법 및 버섯류를 포함하는 건강보조식품 | |
US20070027069A1 (en) | Glucan-protein complex extracted from grifola (Maitake) | |
WO2009102008A1 (ja) | 免疫賦活作用および抗腫瘍作用を有するマイタケ由来の低分子物質 | |
EP2087899B1 (en) | Grifola frondosa-derived substance having anti-influenza virus activity and method for producing the same | |
JPH07284375A (ja) | イザリア型虫草を主成分とする免疫強化食品 | |
CA2590549A1 (en) | Therapeutic agent for polycystic ovary syndrome (pcos) | |
JP2005068112A (ja) | マイタケ由来の抽出物およびグリコプロテイン並びにその製造方法 | |
US6093694A (en) | Antitumor active substances | |
CN1303099C (zh) | 松杉灵芝蛋白多糖混合物及其制备方法与应用 | |
JP2001064195A (ja) | 茸類及び/または酵母類から生理活性物質を採取する方法及びそれらの生理活性剤。 | |
JPH11152230A (ja) | 茸またはその抽出物を含有する組成物 | |
JP2004277414A (ja) | 食用キノコ由来のエストロゲン様活性物質 | |
WO2006126488A1 (ja) | ハナビラタケ抽出物 | |
KR20220076576A (ko) | 버섯으로부터 베타글루칸을 함유하는 수용성 추출물 및 지용성 추출물을 분리하는 방법 | |
CN111011609A (zh) | 一种用于增强哺乳动物的免疫力的组合物 | |
JP2004059558A (ja) | きのこ類から生理活性物質の採取法及びその生理活性物質の製剤及びその使用法 | |
JP2005132810A (ja) | ナメコ、および/または、マイタケの生理活性物質eem−p、その製造方法および剤. | |
KR100893533B1 (ko) | 신규 균주로부터 분리된 면역 증진 및 항암 효과를갖는 β-1,3 글루코만난 분리다당체 | |
KR100729213B1 (ko) | 면역 증강 활성을 갖는 잎새 버섯의 액체배양물로부터분리한 세포외 생체고분자 | |
JP2939206B2 (ja) | 賦形剤 | |
KR102165643B1 (ko) | 표고버섯 당화농축액, 이를 이용한 표고버섯 당화농축분말 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001900649 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027008805 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 551493 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10169099 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027008805 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018064353 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001900649 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001900649 Country of ref document: EP |